Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Status:
Terminated
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well docetaxel or abiraterone acetate work when combined with
androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate
cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as
docetaxel and abiraterone acetate, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Antihormone therapy, such as ADT may lessen the amount of androgen made by the
body. It is not yet known whether docetaxel or abiraterone acetate work better when combined
with ADT in treating patients with hormone sensitive prostate cancer.